Printer Friendly

ADRIA LABORATORIES AND SMITHKLINE BEECHAM AGREE TO CO-PROMOTE MYCOBUTIN

 PHILADELPHIA, May 5 /PRNewswire/ -- SmithKline Beecham (NYSE: SBH) (SB) and Adria Laboratories announced today an agreement in principle to co-promote Adria's recently approved prescription drug, Mycobutin (rifabutin).
 Mycobutin is the only antibiotic approved for the prevention of Mycobacterium avium complex (MAC), a life-threatening bacterial infection common in late-stage AIDS. MAC results in drastic weight loss, anemia and poor absorption of nutrients.
 It is estimated that 20-25 percent of people with AIDS suffer from MAC. There are an estimated 190,000 cases of AIDS in the U.S., and MAC is the fastest growing infection among AIDS patients.
 Under the agreement, SmithKline Beecham and Adria will co-promote rifabutin using Adria's trademark Mycobutin in the United States. Adria will have similar co-promotion rights to a product selected by SmithKline Beecham. Mycobutin will be promoted by SmithKline Beecham's 230-person hospital sales force.
 "Our objective in this agreement is to further strengthen our hospital product line," said Dr. Jerry Karabelas, president of SmithKline Beecham's pharmaceutical business in North America. "Mycobutin is a very promising product."
 SmithKline Beecham -- one of the world's leading healthcare companies -- discovers, develops, manufactures and markets human and animal pharmaceuticals, health-related consumer products and over-the- counter medicines and clinical laboratory testing services.
 Adria Laboratories, based in Dublin, Ohio, is a recognized leader in oncology drug research and development.
 /delval/
 -0- 5/5/93
 /CONTACT: Jeremy Heymsfeld of SmithKline Beecham, 215-751-5166/
 (SBH)


CO: SmithKline Beecham; Adria Laboratories ST: Pennsylvania, Ohio IN: MTC SU:

MK -- PH003 -- 4730 05/05/93 09:06 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 5, 1993
Words:250
Previous Article:PRESBYTERIAN MEDICAL CENTER HIRES ARA AND SPECTAGUARD INC. TO PROVIDE NON-MEDICAL SERVICES
Next Article:1,000-PASSENGER CRUISE SHIP MAKES DAYLONG STOP IN ABERDEEN
Topics:


Related Articles
SIGMA-TAU, SMITHKLINE BEECHAM ANNOUNCE AGREEMENT FOR CO-PROMOTION OF ALCAR IN UNITED STATES
CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
IDEC PHARMACEUTICALS AND SMITHKLINE BEECHAM ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE 'PRIMATIZED' ANTIBODIES FOR ARTHRITIS
SMITHKLINE BEECHAM AND DERMIK LABORATORIES SIGN CO-MARKETING AGREEMENT FOR BACTROBAN
ADRIA ANNOUNCES FINALIZATION OF MYCOBUTIN CO-PROMOTION AGREEMENT
ABBOTT AND SMITHKLINE BEECHAM SIGN MARKETING AND DISTRIBUTION AGREEMENT
SMITHKLINE BEECHAM AND EDS ANNOUNCE A JOINT MARKETING AGREEMENT
SMITHKLINE BEECHAM AND QMED ANNOUNCE STRATEGIC ALLIANCE
Scios to Co-Promote SmithKline Beecham's Paxil
Scios to Co-Promote SmithKline Beecham's Paxil

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters